Greenland Mines (NASDAQ: GRML) is executing a strategic transformation, announcing a series of corporate milestones that underscore its commitment to becoming a focused rare earths and critical minerals company. The company plans to spin off its biotechnology division in the fourth quarter of 2026, a move that will allow it to concentrate solely on mining assets with significant growth potential.
Nasdaq has formally approved the company's application related to its March 2026 transaction, resolving prior deficiencies and bringing Greenland Mines into full compliance with listing requirements. This regulatory milestone removes overhanging uncertainties and provides a stable platform for future operations.
On September 1, Greenland Mines completed the acquisition of the Sarfartoq project in southwest Greenland, following approval by the Government of Greenland. The project is a major neodymium-praseodymium (NdPr) rare earths deposit, essential for permanent magnets used in electric vehicles, wind turbines, and other clean energy technologies. An independent S-K 1300 Initial Assessment for the ST1 deposit estimated a high-case pre-tax net present value of approximately $2.05 billion and a pre-tax internal rate of return of 118.6%, highlighting the project's robust economics.
The company projects that annual NdPr oxide production from ST1 will equal approximately 34% of current NdPr oxide refining outside China, based on 2025 consumption levels, during each of the project's nine scheduled operating years. This positions Greenland Mines as a significant non-Chinese supplier of critical magnet metals, addressing supply chain vulnerabilities in the West.
In conjunction with these developments, Greenland Mines is reshaping its board. Riad El-Dada and Dr. Shalom Hirschman are stepping down, and capital markets veteran Jason Hawkins is joining. This leadership refresh brings extensive financial expertise to guide the company as it advances Sarfartoq and its Skaergaard palladium-gold-platinum project.
The strategic spin-off of the biotech division will allow Greenland Mines to unlock shareholder value by separating its mining and biotech operations. The biotech division includes Klotho’s KLTO-202, a primary indication for ALS, which will become an independent entity. This move enables each division to pursue its own strategic goals with greater focus and efficiency.
Greenland Mines' strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals, and selected midstream processing opportunities. The company is also advancing its broader North Atlantic Critical Metals Corridor vision, linking Greenland resources with allied downstream jurisdictions and industrial infrastructure, thereby enhancing supply chain security for Western nations.
As the world transitions to clean energy, the demand for rare earth elements is soaring. Greenland Mines is positioning itself at the forefront of this critical minerals supply chain, offering investors a pure-play opportunity in the sector. The successful completion of the Sarfartoq acquisition and the planned biotech spin-off mark pivotal steps in the company's evolution, promising significant long-term value creation.
For more information on the full press release, visit https://ibn.fm/QN1U9. The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML.
